Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002310657 | SCV000319490 | pathogenic | Familial thoracic aortic aneurysm and aortic dissection | 2018-04-01 | criteria provided, single submitter | clinical testing | The p.G699D pathogenic mutation (also known as c.2096G>A), located in coding exon 30 of the COL3A1 gene, results from a G to A substitution at nucleotide position 2096. The glycine at codon 699 is replaced by aspartic acid, an amino acid with similar properties. The majority (approximately two-thirds) of COL3A1 mutations identified to date have involved the substitution of another amino acid for glycine within the triple-helical domain (Pepin MG et al. Genet Med. 2014;16(12):881-8; Frank M et al. Eur J Hum Genet. 2015;23(12):1657-64). This particular glycine substitution was detected in an individual with vascular Ehlers-Danlos syndrome (vEDS, historically described as EDS type IV) and has been described as de novo, although details were limited (Pepin MG et al. Genet. Med., 2014 Dec;16:881-8). Internal structural analysis has demonstrated that this alteration disrupts the characteristic G-X-Y motif in the COL3A1 protein and inserts a bulky side chain into a sterically-constrained region (Bella J et al. Science. 1994;266:75-81; Hohenester E et al. Proc. Natl. Acad. Sci. U.S.A. 2008;105:18273-7; Ambry internal data). Additionally, an alternate amino acid substitution at this position, p.G699R (historically described as p.G532R), has also been reported in an individual with vEDS (Pepin M et al. N. Engl. J. Med., 2000 Mar;342:673-80). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Collagen Diagnostic Laboratory, |
RCV000087710 | SCV000120603 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |